Published by Frank Prenesti on 9th December 2024
(Sharecast News) - GSK said the US Food and Drug Administration has agreed to look at data from its MATINEE study to support the regulatory review process to obtain a new use of its Nucala drug as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).